Adalimumab induces deep remission in patients with Crohn's disease

Clicks: 223
ID: 268728
2014
In an exploratory study of patients with moderate to severe ileocolonic CD who received adalimumab induction and maintenance therapy, patients achieving deep remission appeared to have better 1-year outcomes than those not achieving deep remission. These findings should be validated in large, prospe …
Reference Key
jf2014clinicaladalimumab Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Colombel JF;Rutgeerts PJ;Sandborn WJ;Yang M;Camez A;Pollack PF;Thakkar RB;Robinson AM;Chen N;Mulani PM;Chao J;;
Journal clinical gastroenterology and hepatology : the official clinical practice journal of the american gastroenterological association
Year 2014
DOI DOI not found
URL
https://www.pubmed.gov/23856361/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male middle aged Remission Induction Randomized Controlled Trial Antibodies Monoclonal Humanized / therapeutic use* anti-inflammatory agents / therapeutic use* crohn disease / drug therapy* placebos / administration & dosage jean-frédéric colombel adalimumab crohn disease / pathology pmid:23856361 doi:10.1016/j.cgh.2013.06.019 paul j rutgeerts jingdong chao

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.